Ranibizumab for Persistent Diabetic Macular Edema after Bevacizumab Treatment. Issue 2 (March 2017)

• Record Type: Journal Article
• Authors: Katz, Gabriel; Moisseiev, Elad; Goldenberg, Dafna; Moisseiev, Joseph; Lomnicky, Yosef; Abend, Yitzchak; Treister, Giora; Levkovitch-Verbin, Hani
• Is Part Of: European journal of ophthalmology. Volume 27:Issue 2(2017)
• Page Start: 210
• Page End: 214
• Publication Date: 2017-03
• Subjects: Bevacizumab -- Central retinal thickness -- Diabetic macular edema -- Ranibizumab -- Switch -- Visual acuity; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.5301/ejo.5000838
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: To evaluate the efficacy of switching from bevacizumab to ranibizumab in patients with diabetic macular edema (DME). Methods: This was a retrospective study of patients with DME initially treated with bevacizumab and switched to ranibizumab. Visual acuity (VA) and central retinal thickness (CRT) were retrieved at fixed timepoints prior to and after the switch. Results: Forty eyes of 32 patients were included in the study. The difference in VA between any of these fixed timepoints was not statistically significant. A significant gain in VA was found in eyes that lost more than 0.1 logMAR during treatment with the last 3 bevacizumab injections. The mean CRT was significantly lower after the first 3 ranibizumab injections and at the final follow-up (p<0.001), a 67 ± 14 μm and 78 ± 18 μm reduction in thickness, respectively. Conclusions: Switching to ranibizumab resulted in a significant decrease in the CRT of eyes with DME, and should be considered when there is a lack of response or deterioration while on bevacizumab injections. A significant gain in VA was observed in a subgroup of eyes that lost more than one line while receiving the last 3 bevacizumab injections prior to the switch.